Artoss

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Artoss sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials 1 currently recruiting 1 completed upper quartile by trial count

Artoss: 4 sponsored US clinical trials, 1 recruiting.

Artoss sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. The most-studied condition in this pipeline is Fractures, Bone, with 1 trials.

Upper-quartile sponsor footprint

Artoss sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

4 total, page 1 of 1

RECRUITING

Prospective Registry to Evaluate Outcomes of NanoBone® Bone Graft in Acute Trauma

NCT06256458
ACTIVE NOT RECRUITING NA

Rate of Bony Fusion Using NanoBone® Synthetic Bone Graft Versus Local Autologous Bone Graft.

NCT04615260
ACTIVE NOT RECRUITING

Artoss Prospective Spine Registry Outcomes

NCT04439032
COMPLETED

Artoss Foot and Ankle Surgery Registry

NCT04503759

Therapeutic Areas

Fractures, Bone 1
Spondylolisthesis 1
Spinal Fusion 1
Degenerative Disc Disease 1

What is open in the Artoss pipeline

1 recruiting of 4 indexed (25% open); 1 completed (25%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Fractures, Bone (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Artoss: open-pipeline peers nationwide

Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

Artoss sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 3456789 0%20%40%60%80% Total trials Recruiting share Artoss4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action LabAB ScienceAbbott Point of CareAccutar BiotechnologyAdrienne G. Waks
Artoss sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Artoss sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Artoss page

4 registered trials is a research-attention snapshot, not an endorsement of Artoss or any single study.

  • 1 of Artoss's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Fractures, Bone is the condition Artoss studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Fractures, Bone trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Artoss pipeline card: 4 registered trials from official public datasets.Report a data error.